Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Richter's transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Machine learning can identify newly diagnosed patients with CLL at high risk of infection

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Fie J Vojdeman
  • Sarah E M Herman
  • Nikolai Kirkby
  • Adrian Wiestner
  • Mars B van T' Veer
  • Geir Erland Tjønnfjord
  • Maija A Itälä-Remes
  • Eva Kimby
  • Mohammed Z H Farooqui
  • Aaron Polliack
  • Ka Lung Wu
  • Jeanette K Doorduijn
  • Wendimagegn Ghidey Alemayehu
  • Shulamiet Wittebol
  • Tomás Kozák
  • Jan Walewski
  • Martine C J Abrahamse-Testroote
  • Marinus H J van Oers
  • Christian H Geisler
  • Carsten U Niemann
Vis graf over relationer

CD52 is a glycoprotein expressed on normal as well as leukemic immune cells and shed as soluble CD52 (sCD52). We studied sCD52 levels in three CLL cohorts: the 'early', the 'high-risk', and the 'ibrutinib-treated'. The 'high-risk' patients had significantly higher sCD52 levels than the 'early' patients. For the 'early' patients, high sCD52 levels were associated with a significantly shorter time to first treatment. Regarding prognostic factors, no clear correlations with stage, IGHV, or beta-2-microglobulin were found; in a cox multivariate analysis of the 'early' patients, sCD52 and IGHV both had independent prognostic value. Following chemo-immunotherapy, sCD52 decreased in parallel with leukocytes while during ibrutinib treatment and ibrutinib-induced ymphocytosis, sCD52 decreased along with lymph node reductions. In vitro IgM stimulation of CLL cells led to increased sCD52 levels in the medium. Our findings indicate that sCD52 reflects disease activity and potentially treatment efficacy in CLL.

OriginalsprogEngelsk
TidsskriftLeukemia and Lymphoma
Vol/bind58
Udgave nummer10
Sider (fra-til)2356-2362
Antal sider7
ISSN1042-8194
DOI
StatusUdgivet - okt. 2017

ID: 51608561